Jorg Lippert

Kaiser Wilhelm Allee 1
Leverkusen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Reply of the authors: "Polycystic ovary syndrome and type 2 diabetes risk: the need to look beyond obesity".

Reply of the authors: "Polycystic ovary syndrome and type 2 diabetes risk: the need to look beyond obesity".

Journal: Fertility and sterility

Published: May 11, 2026

An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design.

An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 29, 2025

Dialogical meanderings - evaluation framework and learnings from stakeholder involvement in the co-design of a participatory systematic review.

Dialogical meanderings - evaluation framework and learnings from stakeholder involvement in the co-design of a participatory systematic review.

Journal: Research involvement and engagement

Published: March 12, 2025

Polycystic ovary syndrome and elevated body mass index independently increase type 2 diabetes risk with obesity-mediated risk dominating: a real-world data analysis of US patients.

Polycystic ovary syndrome and elevated body mass index independently increase type 2 diabetes risk with obesity-mediated risk dominating: a real-world data analysis of US patients.

Journal: Fertility and sterility

Published: March 07, 2025

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference.

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 19, 2024

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.

Journal: Diabetes, obesity & metabolism

Published: September 06, 2023

Model-Informed Drug Development: Steps Toward Harmonized Guidance.

Model-Informed Drug Development: Steps Toward Harmonized Guidance.

Journal: Clinical pharmacology and therapeutics

Published: May 10, 2023

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 31, 2022

Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Journal: Clinical pharmacokinetics

Published: March 24, 2022

Baseline clusters and the response to positive airway pressure treatment in obstructive sleep apnoea patients: longitudinal data from the European Sleep Apnea Database cohort.

Baseline clusters and the response to positive airway pressure treatment in obstructive sleep apnoea patients: longitudinal data from the European Sleep Apnea Database cohort.

Journal: ERJ open research

Published: March 15, 2022

Data-driven identification of heart failure disease states and progression pathways using electronic health records.

Data-driven identification of heart failure disease states and progression pathways using electronic health records.

Journal: Scientific reports

Published: October 18, 2021

Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.

Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.

Journal: Clinical pharmacokinetics

Published: October 08, 2021

Showing 1-12 of 51

Last Updated: 09/26/2026